One-shot immunization with Sputnik Light (the first component of Sputnik V vaccine) is effective against SARS-CoV-2 Delta variant: efficacy data on the use of the vaccine in civil circulation in Moscow
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Vaccination remains the most effective response to the COVID-19 pandemic. Most vaccines use two-dose regimens. In turn, single-dose vaccines also have high potential, since, on the one hand, they simplify the vaccination program, make it more accessible and convenient for more people around the world, and on the other hand, they are better suited for subsequent revaccination. However, there is not enough data on the effectiveness of single-dose vaccine variants against new genetic lines to assess their current potential. It is not clear how much a single dose of immunization protects against the globally dominant delta variant. In this work, we investigated the effectiveness of a single dose vaccine (Sputnik Light, the first component of Sputnik V vaccine) against the Delta variant in Moscow.
Methods
To assess the effectiveness of one dose of viral vector vaccine based on rAd26 against the delta variant in Moscow, we used data from the Moscow registries of vaccination against COVID-19 and the incidence of COVID-19. The availability of data on the number of seropositive residents of Moscow made it possible to consider the size of the immune layer formed because of a previous COVID-19 disease or vaccination. To calculate the effectiveness, the proportion of COVID-19 cases among those vaccinated with a single dose and the proportion of cases among those who were not vaccinated in July 2021.
Results
Our data indicate that throughout July 2021, the dominant variant of the coronavirus at the level of 99.5% in Moscow was the SARS-CoV-2 delta variant and its subsidiary lines. Considering the immune layer of 46% allowed us to calculate the effectiveness of a one-shot vaccine against the delta variant in Moscow during the first three months after vaccination at the level of 69.85% (95% confidence interval [CI], 64.08 to 74.70). In the 18-29-year-old group, the overall vaccine efficacy against the delta variant was 88.61%, in the 18-59 group - 75.28%. Sputnik Light demonstrates higher efficacy against Delta variant than many two-shot vaccines.
Conclusion
The results indicate a high efficacy of a single immunization first component of Sputnik V vaccine against delta variant among young and middle-aged people, at least during the first 3 months after receiving the one-shot vaccine.
Article activity feed
-
SciScore for 10.1101/2021.10.08.21264715: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Written informed consent was obtained from all subjects in accordance with the order of the Ministry of Health of the Russian Federation of July 21, 2015 N 474n.
IRB: The study was submitted to the Local Ethics Committee of the Gamaleya Center.Sex as a biological variable not detected. Randomization For this monitoring, randomized groups of samples were formed among patients admitted routinely for treatment in “non-COVID” hospitals. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources The statistical analysis was done using Microsoft Excel, and GraphPad Prism v. 9.2. Microsoft Excelsuggested: (Microsoft Excel, RRID:SCR_016137)GraphPad…SciScore for 10.1101/2021.10.08.21264715: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Written informed consent was obtained from all subjects in accordance with the order of the Ministry of Health of the Russian Federation of July 21, 2015 N 474n.
IRB: The study was submitted to the Local Ethics Committee of the Gamaleya Center.Sex as a biological variable not detected. Randomization For this monitoring, randomized groups of samples were formed among patients admitted routinely for treatment in “non-COVID” hospitals. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources The statistical analysis was done using Microsoft Excel, and GraphPad Prism v. 9.2. Microsoft Excelsuggested: (Microsoft Excel, RRID:SCR_016137)GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Evaluation of effectiveness during the first three months can be attributed to the limitation of our study. The choice of such an interval was caused by the fact that truly mass vaccination in Moscow began in April 2021, when the Moscow authorities began to tighten requirements for vaccination among people working in the service sector. Thus, many partially vaccinated people met dominant delta during summer 2021. Meanwhile, even for immunization with two doses, the revaccination period is set at six months after the primary immunization, so that the assessment of efficacy based on the first three months is an informative assessment. Our results show that in age cohorts, the efficacy of a single-dose vaccine against the delta variant differs. Among young 18-29 years old, the effectiveness for the vaccine was 88.61% (95% CI, 78.81-93.88), in general among the 18-59 age group - 75.28 (95% CI, 69.24-80.13). However, with age, the effectiveness of the vaccine tended to decrease and in the group over 60 it was about 52%. Further studies are needed to determine the conditions for revaccination for patients who received the only one dose of the vaccine in different age cohorts.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
